On September 6, 2018, news releases that Guardant, an oncology liquid biopsy test company in the Bay Area, has filed for an IPO. Medcity News here. At Nanylze, here.
Medicare LCD coverage for Guardant was finalized over the summer, here.
Underwriters include JP Morgan, B of A Merrill Lynch, Cowen, Leerink, William Blair.
For a July 2018 Bloomberg article about a potential pending Guardant IPO, here.
As noted at Nanylze, Foundation Medicine rolled out a next-generation of its own LDT liquid biopsy test, now called FoundationOne Liquid, September 2018, here.
For a historical comparison, the archived FMI S-1 filing from 2015, here.